Accuray Amends Dedication Capital Consulting Agreement, Cuts Fees

Accuray ( (ARAY) ) has issued an update.

On April 1, 2026, Accuray amended its consulting agreement with Dedication Capital, an affiliate of director Steven F. Mayer, cutting by 50% the base consulting fee after March 31, 2026, and minimum cash incentive amounts tied to the fiscal year ended June 30, 2026, and the fiscal quarter ended September 30, 2026. The company also accelerated time-based vesting on 916,336 initial restricted shares and all performance stock awards as of April 1, 2026, extended the consulting end date to October 31, 2026, and left 333,004 restricted shares to vest on that date, a package expected to generate at least $362,500 in cash savings for Accuray.

The most recent analyst rating on (ARAY) stock is a Hold with a $0.40 price target. To see the full list of analyst forecasts on Accuray stock, see the ARAY Stock Forecast page.

Spark’s Take on ARAY Stock

According to Spark, TipRanks’ AI Analyst, ARAY is a Underperform.

The score is held down primarily by weak financial performance (return to losses and high leverage) and bearish technicals (price far below key moving averages with negative MACD). A guidance cut and margin/cash pressure from the latest earnings call reinforce near-term risk, while strong orders/backlog and transformation actions provide only partial support.

To see Spark’s full report on ARAY stock, click here.

More about Accuray

Accuray Incorporated is a medical technology company that develops and markets precision radiation therapy systems for treating cancer and other diseases. The company focuses on advanced, image-guided and adaptive radiotherapy solutions used by hospitals and cancer centers worldwide to improve treatment accuracy and patient outcomes in the oncology care market.

Average Trading Volume: 1,168,085

Technical Sentiment Signal: Sell

Current Market Cap: $49.75M

See more insights into ARAY stock on TipRanks’ Stock Analysis page.